Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02950493 · ClinicalTrials.gov registry record · NA
Use of Reactivated DEFINITY or LUMASON in Patients Undergoing Rest or Stress Echocardiography
A NA study, sponsored by University of Nebraska.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02950493 is a NA study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 20 participants.
The verdict
NCT02950493, a NA study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Use of Reactivated DEFINITY® in or LUMASON Patients Undergoing Rest or Stress Echo Purpose of the study: Each patient undergoing a rest or stress echocardiogram uses a full vial of DEFINITY® or LUMASON contrast agent. During infusion, this often condenses back to its liquid phase due to manual pressure applied in the syringe. At this point, it is not optimal to be used at current ultrasound settings for stress echocardiography. This research project will test whether this condensed DEFINITY® or LUMASON can be reactivated by ultrasound using the same transducer used to image the patient. Eligibility: Same criteria as required for stress echo procedure. Interventions and Evaluations: Inject condensed DEFINITY® or LUMASON at end of stress test Follow Up: The patient would be observed by echo lab staff for half an hour following completion of the stress test. There would be no longitudinal follow up.
Interventions
- OTHER perflutren lipid microsphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-04-06 |
| Est. Completion | 2024-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02950493
The ClinicalTrials.gov registry entry for NCT02950493 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which perflutren lipid microsphere is the first listed.
NCT02950493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02950493 about?
NCT02950493 is a clinical study titled "Use of Reactivated DEFINITY or LUMASON in Patients Undergoing Rest or Stress Echocardiography". Use of Reactivated DEFINITY® in or LUMASON Patients Undergoing Rest or Stress Echo Purpose of the study: Each patient undergoing a rest or stress echocardiogram uses a full vial of DEFINITY® or LUMASON contrast agent. During infusion, this often condenses back to its liquid phase due to manual press...
What is the current status of trial NCT02950493?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2017-04-06. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT02950493?
The interventions under investigation include: perflutren lipid microsphere (OTHER).
Who is sponsoring clinical trial NCT02950493?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.